Douglas C. Saffran

4.1k total citations · 2 hit papers
33 papers, 3.2k citations indexed

About

Douglas C. Saffran is a scholar working on Immunology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Douglas C. Saffran has authored 33 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 13 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Douglas C. Saffran's work include Chronic Lymphocytic Leukemia Research (8 papers), Immunodeficiency and Autoimmune Disorders (8 papers) and Prostate Cancer Treatment and Research (5 papers). Douglas C. Saffran is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Immunodeficiency and Autoimmune Disorders (8 papers) and Prostate Cancer Treatment and Research (5 papers). Douglas C. Saffran collaborates with scholars based in United States, Canada and Finland. Douglas C. Saffran's co-authors include Owen N. Witte, David J. Rawlings, Satoshi Tsukada, Daniel Afar, Ornella Parolini, Mary Ellen Conley, Ivana Klisak, Shirley G. Quan, R.Cutler Allen and T. Mohandas and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Douglas C. Saffran

33 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia

1993 1.1k citations Satoshi Tsukada, Douglas C. Saffran et al. Cell profile →
Mutation of Unique Region of Bruton's Tyrosine Kinase in Immunodeficient XID Mice

1993 726 citations David J. Rawlings, Douglas C. Saffran et al. profile →

Peers

Douglas C. Saffran

IMMUN

GENET

HEMAT

ONCOL

Anne B. Satterthwaite United States

Rajat Bannerji United States

Stefan Früehauf Germany

William C. Manning United States

Mary L. Bath Australia

Meike Burger Germany

Mathijs Baens Belgium

Serge Fichelson France

L R Finger United States

Hilmar Quentmeier Germany

Anne B. Satterthwaite United States

Douglas C. Saffran

2.5k ×1.3

IMMUN

820 ×0.7

GENET

1.1k ×1.2

402 ×0.7

HEMAT

445 ×0.9

ONCOL

Citations per year, relative to Douglas C. Saffran Douglas C. Saffran (= 1×) peers Anne B. Satterthwaite

Countries citing papers authored by Douglas C. Saffran

Since Specialization

Citations

This map shows the geographic impact of Douglas C. Saffran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas C. Saffran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas C. Saffran more than expected).

Fields of papers citing papers by Douglas C. Saffran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas C. Saffran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas C. Saffran. The network helps show where Douglas C. Saffran may publish in the future.

Co-authorship network of co-authors of Douglas C. Saffran

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas C. Saffran. A scholar is included among the top collaborators of Douglas C. Saffran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas C. Saffran. Douglas C. Saffran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saffran, Douglas C., Tressa Hood, Nikolaus D. Obholzer, et al.. (2022). Abstract 2564: CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers. Cancer Research. 82(12_Supplement). 2564–2564. 3 indexed citations

Saffran, Douglas C., Tressa Hood, Nikolaus D. Obholzer, et al.. (2022). Abstract 2565: CDK9 inhibitor KB-0742 is active in preclinical models of small-cell lung cancer. Cancer Research. 82(12_Supplement). 2565–2565. 1 indexed citations

Carvajal, Luis A., Mick McKeown, Tressa Hood, et al.. (2022). SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents. Blood. 140(Supplement 1). 5932–5933. 2 indexed citations

Bush, Tammy L., Marc Payton, Scott Heller, et al.. (2013). AMG 900, a Small-Molecule Inhibitor of Aurora Kinases, Potentiates the Activity of Microtubule-Targeting Agents in Human Metastatic Breast Cancer Models. Molecular Cancer Therapeutics. 12(11). 2356–2366. 44 indexed citations

Tsukada, Satoshi, Douglas C. Saffran, David J. Rawlings, et al.. (2012). Pillars Article: Deficient Expression of a B Cell Cytoplasmic Tyrosine Kinase in Human X-linked Agammaglobulinemia. Cell. 1993. 72: 279–290. The Journal of Immunology. 188(7). 2936–2947. 2 indexed citations

Coxon, Angela, Stephen A. Kaufman, Man Xu, et al.. (2012). Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models. Molecular Cancer. 11(1). 70–70. 19 indexed citations

Teffera, Yohannes, Loren Berry, Rachael Brake, et al.. (2012). Impact of Hydrolysis-Mediated Clearance on the Pharmacokinetics of Novel Anaplastic Lymphoma Kinase Inhibitors. Drug Metabolism and Disposition. 41(1). 238–247. 5 indexed citations

Kaufman, Stephen A., Man Xu, Hongyu Wang, et al.. (2010). Abstract 1380: Antitumor activity of motesanib alone and in combination with chemotherapy in xenograft models of human non-small cell lung cancer. Cancer Research. 70(8_Supplement). 1380–1380. 1 indexed citations

Afar, Daniel, Igor Vivanco, René Hubert, et al.. (2001). Catalytic cleavage of the androgen-regulated TMPRSS2 protease results in its secretion by prostate and prostate cancer epithelia.. PubMed. 61(4). 1686–92. 199 indexed citations

10.

Saffran, Douglas C., Robert E. Reiter, Aya Jakobovits, & Owen N. Witte. (1999). Target Antigens for Prostate Cancer Immunotherapy. Cancer and Metastasis Reviews. 18(4). 437–449. 23 indexed citations

11.

Walsh, Craig M., et al.. (1996). Cell-mediated cytotoxicity results from, but may not be critical for, primary allograft rejection. The Journal of Immunology. 156(4). 1436–1441. 37 indexed citations

12.

Rawlings, David J., et al.. (1995). Development of btk Transgenic Mice. Current topics in microbiology and immunology. 194. 363–370. 6 indexed citations

13.

Goga, Andrei, Jami McLaughlin, Daniel Afar, Douglas C. Saffran, & Owen N. Witte. (1995). Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 82(6). 981–988. 217 indexed citations

14.

Zhu, Qili, Miqin Zhang, David J. Rawlings, et al.. (1994). Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA).. The Journal of Experimental Medicine. 180(2). 461–470. 72 indexed citations

15.

Saffran, Douglas C., Ornella Parolini, David J. Rawlings, et al.. (1994). A Point Mutation in the SH2 Domain of Bruton's Tyrosine Kinase in Atypical X-Linked Agammaglobulinemia. New England Journal of Medicine. 330(21). 1488–1491. 98 indexed citations

16.

Tsukada, Satoshi, Douglas C. Saffran, David J. Rawlings, et al.. (1993). Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 72(2). 279–290. 1053 indexed citations breakdown →

17.

Saffran, Douglas C., et al.. (1993). Distinctive growth requirements and gene expression patterns distinguish progenitor B cells from pre-B cells.. The Journal of Experimental Medicine. 177(4). 915–923. 50 indexed citations

18.

Saffran, Douglas C., et al.. (1992). Establishment of a Reproducible Culture Technique for the Selective Growth of B-Cell Progenitors. Current topics in microbiology and immunology. 182. 37–43. 10 indexed citations

19.

Saffran, Douglas C., et al.. (1991). SEPARATION OF ALLOSTIMULATORY AND NATURAL SUPPRESSOR/STEM CELL FUNCTIONS OF MURINE BONE MARROW—IMPLICATIONS FOR BONE MARROW TRANSPLANTATION. Transplantation. 52(4). 680–685. 4 indexed citations

20.

Saffran, Douglas C. & Sharwan K. Singhal. (1990). Further characterization of murine bone marrow-derived natural suppressor cells. Potential relationships between NS and NK/LAK activities. Cellular Immunology. 128(1). 301–313. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact